Innovating the Fight Against Cancer
WITH PRECISION
At IDRx, we aim to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong patients’ response to therapy.
OUR GOAL IS CLEAR
To transform the lives of patients with Gastrointestinal Stromal Tumor (GIST)
We are advancing our lead clinical-stage program, IDRX-42, for the treatment of GIST – the most common type of soft tissue sarcoma occurring in of the gastrointestinal tract. IDRX-42 has the potential to treat the large majority of GIST tumors that are driven by multiple types of mutations in a gene called KIT.